Literature DB >> 2464031

Amino acid substitutions in VH CDR2 change the idiotype but not the antigen-binding of monoclonal antibodies to alpha(1----6)dextrans.

S K Sikder1, P Borden, F Gruezo, P N Akolkar, S B Bhattacharya, S L Morrison, E A Kabat.   

Abstract

An idiotype defined by mAb and polyclonal antibodies to 10.16.1, an anti-alpha(1----6) dextran was previously reported to be expressed on most BALB/c anti-alpha(1----6)dextrans with groove-type sites and to involved CDR3 and probably CDR2. By comparing amino acid sequences of VH and VL derived from cDNA of idiotype+ and idiotype- anti-alpha(1----6)dextran hybridoma proteins, an idiotope was assigned to VH CDR2. Substitution of phenylalanine for leucine at residue 52 in CDR2 coupled with amino acid changes at either residue 58 or residues 57 and 60 abolished expression of this idiotype without affecting Ag binding.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464031

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

Review 1.  Content and dynamics of the human antibody variable region repertoire to the Haemophilus influenzae type b polysaccharide.

Authors:  D C Reason; A H Lucas
Journal:  Springer Semin Immunopathol       Date:  1993

2.  A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles.

Authors:  E H Sasso; K Willems van Dijk; A P Bull; E C Milner
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

3.  Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide alpha(1-->6)dextran.

Authors:  D Wang; S M Wells; A M Stall; E A Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

4.  Molecular characterization of a cross-reactive idiotope on human immunoglobulins utilizing the VH4-21 gene segment.

Authors:  K N Potter; Y Li; V Pascual; R C Williams; L C Byres; M Spellerberg; F K Stevenson; J D Capra
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.